Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6419451 | 0.88 | ALDH1A1 (0.43) | ALDH1A1HSD17B10MTNR1AMTNR1BHPGD | |
| SCHEMBL18719607 | 0.85 | POLB (0.43) | MEN1KMT2AMTNR1AMTNR1BHTR2C | |
| SCHEMBL11484971 | 0.84 | HSD17B10 (0.52) | ALDH1A1MEN1KMT2AHSD17B10TDP1 | |
| SCHEMBL15624358 | 0.84 | KMT2A (0.55) | ALDH1A1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL23105683 | 0.82 | RIPK1 (0.49) | MTNR1AMTNR1BHTR2CSLC6A4CACNA1G | |
| SCHEMBL8164937 | 0.82 | HTR2C (0.38) | MTNR1AMTNR1BHTR2CSLC6A4PDK2 | |
| SCHEMBL15747297 | 0.82 | HTR2C (0.43) | ALDH1A1HTR2CSLC6A4SMN1; SMN2CACNA1G | |
| SCHEMBL15261600 | 0.81 | HTR2C (0.43) | MEN1KMT2AHSD17B10HTR2CSLC6A4 | |
| SCHEMBL6418683 | 0.81 | SSTR4 (0.39) | ALDH1A1MEN1KMT2AHSD17B10MTNR1A | |
| SCHEMBL4719084 | 0.80 | SSTR4 (0.46) | ALDH1A1HSD17B10MTNR1AMTNR1BHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2329821-B1 | Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema | GLAXOSMITHKLINE LLC (US) | 2012-08-22 | — | — | EP | disclosed |
| CN-101370505-B | Treatment of ocular neovascular disorders such as macular degeneration, angioid streaks, uveitis and macular edema | SMITHKLINE BEECHAM CORP | 2012-03-21 | — | — | CN | disclosed |
| EP-2329821-A1 | Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema | GlaxoSmithKline LLC (US) | 2011-06-08 | — | — | EP | disclosed |
| EP-1968594-B1 | TREATMENT OF OCULAR NEOVASCULAR DISORDERS SUCH AS MACULAR DEGENERATION, ANGIOD STREAKS, UVEITIS AND MACULAR EDEMA | GLAXOSMITHKLINE LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| CN-101370505-A | Treatment of ocular neovascular disorders such as macular degeneration, angioid streaks, uveitis and macular edema | SMITHKLINE BEECHAM CORP (US) | 2009-02-18 | — | — | CN | disclosed |
| US-20080293691-A1 | Treatment Method | SMITHKLINE BEECHAM CORPORATION | 2008-11-27 | — | — | US | disclosed |
| EP-1968594-A2 | TREATMENT OF OCULAR NEOVASCULAR DISORDERS SUCH AS MACULAR DEGENERATION, ANGIOD STREAKS, UVEITIS AND MACULAR EDEMA | SmithKline Beecham Corporation (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007064752-A2 | TREATMENT OF OCULAR NEOVASCULAR DISORDERS SUCH AS MACULAR DEGENERATION, ANGIOD STREAKS, UVEITIS AND MACULAR EDEMA | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-0957917-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6825188-B2 | MORE POTENT INHIBITORS OF THE VITRONECTIN RECEPTOR THAN THE FIBRINOGEN | SMITHKLINE BEECHAM CORPORATION | 2004-11-30 | — | — | US | disclosed |
| EP-0946180-A4 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORP (US) | 2003-07-23 | — | — | EP | disclosed |
| CN-1114403-C | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 2003-07-16 | — | — | CN | disclosed |
| US-20030125317-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-07-03 | — | — | US | disclosed |
| EP-0957917-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-05-15 | — | — | EP | disclosed |
| US-20020032187-A1 | Method for stimulating bone formation | SMITHKLINE BEECHAM CORPORATION | 2002-03-14 | — | — | US | disclosed |
| CN-1238689-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1999-12-15 | — | — | CN | disclosed |
| EP-0957917-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-24 | — | — | EP | disclosed |
| EP-0946180-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998015278-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-16 | — | — | WO | disclosed |
| WO-1998014192-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032187-A1 | Method for stimulating bone formation | BMP2, BMP4, SOST | ALDH1A1 2599/4885MEN1 2235/4885KMT2A 4771/4885 |
| US-20080293691-A1 | Treatment Method | ALDH1A2, KDR, VEGFA | ALDH1A1 166/4885MEN1 4085/4885KMT2A 1737/4885 |
| US-20030125317-A1 | Vitronectin receptor antagonists | VCAM1, GPR174, ADGRF1 | ALDH1A1 3956/4885MEN1 1246/4885KMT2A 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.